Guardant Health (NASDAQ:GH) CEO Sells $17,638,207.88 in Stock

Posted by George Bondi on Jul 3rd, 2026

Guardant Health, Inc. (NASDAQ:GH – Get Free Report) CEO Amirali Talasaz sold 116,972 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $150.79, for a total transaction of $17,638,207.88. Following the transaction, the chief executive officer owned 1,881,336 shares in the company, valued at $283,686,655.44. This trade represents a 5.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The shares were sold at an average price of $151.54, for a total value of $21,674,463.12.
On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00.
On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The stock was sold at an average price of $100.32, for a total transaction of $5,016,000.00.

Guardant Health Price Performance

GH stock opened at $167.98 on Friday. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $172.60. The firm has a fifty day moving average price of $118.33 and a two-hundred day moving average price of $105.66. The firm has a market cap of $22.27 billion, a price-to-earnings ratio of -49.55 and a beta of 1.59.

Hedge Funds Weigh In On Guardant Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. World Investment Advisors acquired a new stake in Guardant Health during the fourth quarter valued at approximately $1,664,000. Segall Bryant & Hamill LLC grew its holdings in shares of Guardant Health by 57.8% during the third quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock worth $19,066,000 after purchasing an additional 111,822 shares during the last quarter. TD Asset Management Inc raised its holdings in shares of Guardant Health by 16.1% in the third quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock valued at $11,797,000 after buying an additional 26,210 shares during the last quarter. Algert Global LLC lifted its position in Guardant Health by 169.1% during the 3rd quarter. Algert Global LLC now owns 120,114 shares of the company’s stock worth $7,505,000 after buying an additional 75,474 shares in the last quarter. Finally, Capricorn Fund Managers Ltd lifted its position in Guardant Health by 197.8% during the 4th quarter. Capricorn Fund Managers Ltd now owns 107,787 shares of the company’s stock worth $11,009,000 after buying an additional 71,587 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on GH shares. JPMorgan Chase & Co. upped their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a report on Thursday. Piper Sandler set a $127.00 target price on Guardant Health in a research report on Thursday, May 21st. Barclays boosted their price objective on shares of Guardant Health from $120.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Finally, Guggenheim upped their price target on shares of Guardant Health from $135.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $147.32.

Read Our Latest Research Report on Guardant Health

Guardant Health Company Profile

(Get Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.